Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Patient Perspectives on Reirradiation for Recurrent Cancer, to Inform Future Clinical Trial Design.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Computed tomography, ultrasound and fluoroscopy guidance in intra-articular sacroiliac joint injections: A systematic review.

Radiography (London, England : 1995)·2026
Same author

Position statement from the British Society of Blood and Marrow Transplantation and Cellular Therapy on insertional oncogenesis in gene-engineered advanced cell therapy products for treatment of haematological disorders.

British journal of haematology·2025
Same author

Response to 'Dose Accumulation for Pelvic Stereotactic Ablative Radiotherapy Reirradiation. In Regard to Slevin et al.'

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

The long-term outcome and changes in tricuspid regurgitation pressure gradient in dogs diagnosed with pulmonary hypertension and Angiostrongylus vasorum infestation.

The Journal of small animal practice·2025
Same journal

Focal therapy for localized prostate cancer: not all that glitters is gold.

Prostate cancer and prostatic diseases·2026
Same journal

A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care.

Prostate cancer and prostatic diseases·2026
Same journal

En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?

Prostate cancer and prostatic diseases·2026
Same journal

Response to de Riese et al. regarding "methodological and clinical considerations of MRI-based prostate cancer risk calculators".

Prostate cancer and prostatic diseases·2026
Same journal

Methodological and clinical considerations of MRI-based prostate cancer risk calculators.

Prostate cancer and prostatic diseases·2026
Same journal

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?

D Connolly1, A Black, L J Murray

  • 1Department of Urology, Belfast City Hospital, Belfast, Northern Ireland. djconn76@hotmail.com

Prostate Cancer and Prostatic Diseases
|September 3, 2008
PubMed
Summary
This summary is machine-generated.

Repeating an abnormal prostate-specific antigen (PSA) test may not be beneficial. Some prostate cancer patients show decreased PSA levels, so a biopsy decision should not be delayed based on PSA changes.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jul 2, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Area of Science:

  • Urology
  • Oncology
  • Diagnostic Medicine

Background:

  • Elevated prostate-specific antigen (PSA) levels prompt further investigation for prostate cancer.
  • The practice of repeating PSA tests before biopsy is common but its clinical utility is debated.

Purpose of the Study:

  • To evaluate the pattern of PSA changes after an initial abnormal PSA reading.
  • To determine if PSA decrease influences prostate cancer diagnosis and biopsy decisions.

Main Methods:

  • Retrospective analysis of 7052 men with initial PSA levels >= 4.0 ng/ml.
  • Assessed PSA level changes and correlation with prostate cancer diagnosis.

Main Results:

  • 71.2% of men experienced a PSA reduction, with 37.8% falling below 4.0 ng/ml.
  • 43.0% of men diagnosed with prostate cancer showed a decrease in PSA levels.

Conclusions:

  • Short-term PSA decreases can occur even in men with prostate cancer, including high-grade disease.
  • Repeating PSA tests should not influence the decision to proceed with a prostate biopsy.